Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venanprubart in Primary Sjogren's Syndrome
NCT05781451Phase 2Withdrawn
- Sponsor
- Stanford University
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of venanprubart, sponsored by Stanford University. Primary endpoint: Sjogren's Tool for Assessing Response at 12 weeks. Planned start Jan 2025; status: withdrawn.
02
Drugs
venanprubart
Beyond the preview
Go deeper on NCT05781451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781451.